We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

483 hedge funds and large institutions have $10.9B invested in Abiomed Inc in 2019 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 190 increasing their positions, 185 reducing their positions, and 111 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more repeat investments, than reductions

Existing positions increased: 190 | Existing positions reduced: 185

4% less capital invested

Capital invested by funds: $11.4B → $10.9B (-$468M)

14% less funds holding

Funds holding: 559483 (-76)

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

50% less call options, than puts

Call options by funds: $123M | Put options by funds: $247M

59% less first-time investments, than exits

New positions opened: 45 | Existing positions closed: 111

Holders
483
Holders Change
-76
Holders Change %
-13.6%
% of All Funds
10.49%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.09%
New
45
Increased
190
Reduced
185
Closed
111
Calls
$123M
Puts
$247M
Net Calls
-$124M
Net Calls Change
+$10.6M
Name Holding Trade Value Shares
Change
Change in
Stake
Squarepoint
101
Squarepoint
New York
$9.72M +$2.81M +10,590 +40%
Adage Capital Partners
102
Adage Capital Partners
Massachusetts
$9.6M -$5.25M -19,800 -35%
BCIM
103
British Columbia Investment Management
British Columbia, Canada
$9.29M +$4.78M +18,016 +102%
USAA
104
United Services Automobile Association
Texas
$9.22M +$540K +2,036 +6%
Canada Life
105
Canada Life
Manitoba, Canada
$9.12M +$9.29M +35,027 New
Bank of Montreal
106
Bank of Montreal
Ontario, Canada
$8.97M -$1.29M -4,856 -12%
SLAM
107
Swiss Life Asset Management
$8.65M +$1.61M +6,057 +22%
TCM
108
Tekla Capital Management
Massachusetts
$8.52M +$2.32M +8,730 +36%
Toronto Dominion Bank
109
Toronto Dominion Bank
Ontario, Canada
$8.41M +$7.16M +27,003 +72%
ACI
110
AMP Capital Investors
Australia
$8.18M -$4.93M -18,582 -37%
BNP Paribas Asset Management
111
BNP Paribas Asset Management
France
$8.1M +$758K +2,856 +10%
BNP Paribas Financial Markets
112
BNP Paribas Financial Markets
France
$8.07M -$8.07M -30,424 -50%
TD Asset Management
113
TD Asset Management
Ontario, Canada
$7.58M +$108K +407 +1%
Lord, Abbett & Co
114
Lord, Abbett & Co
New Jersey
$7.26M +$3M +11,317 +68%
CSS
115
Cubist Systematic Strategies
Connecticut
$7.25M +$156K +587 +2%
DekaBank Deutsche Girozentrale
116
DekaBank Deutsche Girozentrale
Germany
$7.11M +$5.51M +20,760 +301%
Allianz Asset Management
117
Allianz Asset Management
Germany
$7.03M -$1.77M -6,669 -20%
Kayne Anderson Rudnick Investment Management
118
Kayne Anderson Rudnick Investment Management
California
$7.01M +$3.44M +12,983 +93%
Citigroup
119
Citigroup
New York
$6.98M -$3.91M -14,739 -35%
ORI
120
Oak Ridge Investments
Illinois
$6.87M -$1.17M -4,421 -14%
TW
121
TrinityPoint Wealth
Connecticut
$6.67M
HSBC Holdings
122
HSBC Holdings
United Kingdom
$6.66M -$592K -2,230 -8%
Handelsbanken Fonder
123
Handelsbanken Fonder
Sweden
$6.64M -$1.59M -6,000 -19%
CAM
124
Congress Asset Management
Massachusetts
$6.55M -$163K -615 -2%
VOYA Investment Management
125
VOYA Investment Management
Georgia
$6.53M +$344K +1,295 +5%

ABMD Hedge Fund Activity: Q2 2019 in Review

483 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q2 2019, worth a combined $10.9B — down 4.1% from $11.4B a quarter earlier.

Sellers outnumbered buyers: 111 funds closed out of ABMD and 45 opened new positions — a net loss of 66 holders — while 185 trimmed existing stakes and 190 added.

The largest buyer was Baillie Gifford & Co, adding an estimated $302M. The largest seller was AQR Capital Management, cutting an estimated $121M.

  • 483 institutional investors held Abiomed Inc (ABMD) as of Q2 2019, down from 559 in Q1 2019.
  • Funds reported $10.9B of Abiomed Inc stock for Q2 2019, down 4.1% quarter-over-quarter.
  • 45 funds opened new Abiomed Inc positions in Q2 2019 and 111 closed out, a net change of -66 holders.
  • The largest Abiomed Inc buyer in Q2 2019 was Baillie Gifford & Co, an estimated $302M added.
  • The largest Abiomed Inc seller in Q2 2019 was AQR Capital Management, an estimated $121M sold.

Based on aggregated 13F filings for Q2 2019.